Ruxolitinib as potential targeted therapy for patients with JAK2 rearrangements

Haematologica

Volumn 98, Issue 3, 2013, Pages 404-408

  Chase, Andrew ^a,b   Bryant, Catherine ^a,b   Score, Joannah ^a,b   Haferlach, Claudia ^c   Grossmann, Vera ^c   Schwaab, Juliana ^d   Hofmann, Wolf Karsten ^d   Reiter, Andreas ^d   Cross, Nicholas C P ^a,b  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b WESSEX REGIONAL GENETICS LABORATORY   (United Kingdom)

^c MLL MUNICH LEUKEMIA LABORATORY   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CD135 ANTIGEN; FIBROBLAST GROWTH FACTOR RECEPTOR 1; JANUS KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; RUXOLITINIB; STAT5 PROTEIN; TRANSCRIPTION FACTOR ETV6; ONCOPROTEIN; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE; TEL-JAK2 FUSION PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CHROMOSOME ANALYSIS; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; DISEASE ASSOCIATION; FLUORESCENCE IN SITU HYBRIDIZATION; GENE REARRANGEMENT; HUMAN; HUMAN CELL; IC 50; MALE; MYELOPROLIFERATIVE NEOPLASM; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; GENE AMPLIFICATION; GENE TRANSLOCATION; GENETIC RECOMBINATION; GENETICS; METABOLISM; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; MYELOPROLIFERATIVE DISORDERS; TUMOR CELL LINE;

AGED; CELL LINE, TUMOR; GENE AMPLIFICATION; HUMANS; JANUS KINASE 2; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; MYELOPROLIFERATIVE DISORDERS; ONCOGENE PROTEINS, FUSION; PROTEIN KINASE INHIBITORS; PYRAZOLES; RECOMBINATION, GENETIC; TRANSLOCATION, GENETIC;

EID: 84874510469     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2012.067959     Document Type: Article

References (18)

1. Ho JM, Beattie BK, Squire JA, Frank DA, Barber DL. Fusion of the ets transcription factor TEL to Jak2 results in constitutive Jak-Stat signaling. Blood. 1999;93(12):4354-64.
2. Ho JM, Nguyen MH, Dierov JK, Badger KM, Beattie BK, Tartaro P, et al. TEL-JAK2 constitutively activates the extracellular signal-regulated kinase (ERK), stress-activated protein/Jun kinase (SAPK/JNK), and p38 signaling pathways. Blood. 2002; 100(4):1438-48.
3. Reiter A, Walz C, Watmore A, Schoch C, Blau I, Schlegelberger B, et al. The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2. Cancer Res. 2005; 65(7):2662-7.
4. Griesinger F, Hennig H, Hillmer F, Podleschny M, Steffens R, Pies A, et al. A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11.2) translocation in a patient with a clinically typical chronic myeloid leukemia. Genes Chromosome Cancer. 2005;44(3):329-33.
5. Peeters P, Raynaud SD, Cools J, Wlodarska I, Grosgeorge J, Philip P, et al. Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. Blood. 1997;90(7):2535-40.
6. Najfeld V, Cozza A, Berkofsy-Fessler W, Prchal J, Scalise A. Numerical gain and structural rearrangements of JAK2, identified by FISH, characterize both JAK2617V>F-positive and -negative patients with Ph-negative MPD, myelodysplasia, and B-lymphoid neoplasms. Exp Hematol. 2007;35(11):1668-76.
7. Van Roosbroeck K, Cox L, Tousseyn T, Lahortiga I, Gielen O, Cauwelier B, et al. JAK2 rearrangements, including the novel SEC31A-JAK2 fusion, are recurrent in classical Hodgkin lymphoma. Blood. 2011; 117(15):4056-64.
8. Walz C, Cross NC, Van Etten RA, Reiter A. Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders. Leukemia. 2008; 22(7):1320-34.
9. Smedley D, Demiroglu A, Abdul-Rauf M, Heath C, Cooper C, Shipley J, et al. ZNF198-FGFR1 transforms Ba/F3 cells to growth factor independence and results in high level tyrosine phosphorylation of STATS 1 and 5. Neoplasia. 1999;1(4):349-55.
10. Grand FH, Iqbal S, Zhang L, Russell NH, Chase A, Cross NC. A constitutively active SPTBN1-FLT3 fusion in atypical chronic myeloid leukemia is sensitive to tyrosine kinase inhibitors and immunotherapy. Exp Hematol. 2007;35(11):1723-7.
11. Chase A, Grand FH, Cross NC. Activity of TKI258 against primary cells and cell lines with FGFR1 fusion genes associated with the 8p11 myeloproliferative syndrome. Blood. 2007;110(10):3729-34.
12. Sohal J, Chase A, Goldman JM, Cross NC. Assignment of ZNF262 to human chromosome band 1p34-->p32 by in situ hybridization. Cytogenet Cell Genet. 1999; 85(3-4):306-7.
13. Parganas E, Wang D, Stravopodis D, Topham DJ, Marine JC, Teglund S, et al. Jak2 is essential for signaling through a variety of cytokine receptors. Cell. 1998; 93(3):385-95.
14. Gu TL, Goss VL, Reeves C, Popova L, Nardone J, Macneill J, et al. Phosphotyrosine profiling identifies the KG-1 cell line as a model for the study of FGFR1 fusions in acute myeloid leukemia. Blood. 2006;108(13):4202-4.
15. Shi JG, Chen X, McGee RF, Landman RR, Emm T, Lo Y, et al. The pharmacokinetics, pharmacodynamics, and safety of orally dosed INCB018424 phosphate in healthy volunteers. J Clin Pharmacol. 2011; 51(12):1644-54.
16. Weniger MA, Melzner I, Menz CK, Wegener S, Bucur AJ, Dorsch K, et al. Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation. Oncogene. 2006;25(18):2679-84.
17. Tasian SK, Loi ML. Understanding the biology of CRLF2-overexpressing acute lymphoblastic leukemia. Critical Reviews in Oncogenesis. 2011;16(1-2):13-24.
18. Zhang J, Ding L, Holmfeldt L, Wu G, Heatley SL, Payne-Turner D, et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature. 2012; 481(7380):157-63.